Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies
Theodoros Karantanos,1 Ioannis Politikos,2 Vassiliki A Boussiotis3–5 1General Internal Medicine Section, Boston Medical Center, Boston University School of Medicine, Boston, MA, 2Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York,...
Saved in:
Main Authors: | Karantanos T, Politikos I, Boussiotis VA |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2017
|
Subjects: | |
Online Access: | https://doaj.org/article/a78f0932b2e542a597ae09502b0e554a |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Outcomes and relapse patterns following chemotherapy in advanced Hodgkin lymphoma in the positron emission tomography era
by: Lapuz C, et al.
Published: (2018) -
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma
by: Bhutani D, et al.
Published: (2017) -
Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma
by: Oncale MB, et al.
Published: (2017) -
Profile of brentuximab vedotin and its potential in the treatment of relapsed or refractory Hodgkin lymphoma
by: Illidge T, et al.
Published: (2012) -
IDH1-mutated relapsed or refractory AML: current challenges and future prospects
by: Megías-Vericat JE, et al.
Published: (2019)